Nivolumab Shows Benefit After Progression in Advanced Melanoma

Treatment of advanced melanoma with the checkpoint inhibitor nivolumab beyond RECIST-defined progression resulted in clinical benefit for selected patients, according to pooled, retrospective data from two phase III trials.

Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news